Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

FDA Grants Breakthrough Therapy Designation to Izalontamab Brengitecan in EGFR+ NSCLC

August 18th 2025

Izalontamab brengitecan earned FDA breakthrough therapy designation for EGFR-mutated locally advanced or metastatic NSCLC.

Thoracic Oncology Fellows Forum Is Highlighted by PRO Data and Tarlatamab in SCLC

August 18th 2025

Hematology/oncology fellows shared insights on notable presentations given during the OncLive Fellows Forum on Thoracic Oncology.

The OncFive: Top Oncology Articles for the Week of 8/10

August 16th 2025

Vepdegestrant NDA under FDA review in ESR1-mutated breast cancer, Oncomine Dx Target Test gets greenlit as zongertinib companion diagnostic in NSCLC.

Dr Halmos on Treatment Sequencing in Relapsed/Refractory NSCLC

August 14th 2025

Balazs Halmos, MD, discusses treatment sequencing considerations in the second line and beyond in NSCLC.

Immunotherapy and T-Cell–Directed Therapy Expand Treatment Approaches in Small Cell Lung Cancer

August 14th 2025

Sonam Puri, MD, discusses advances in small cell lung cancer that have expanded treatment options across disease stages.

Unmet Needs Research Aims to Address in Early-Stage NSCLC

August 14th 2025

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss ongoing research in early-stage non–small cell lung cancer.

Dr Riess on Sequencing Considerations for KRAS and BRAF Inhibitors in NSCLC

August 12th 2025

Jonathan Wesley Riess, MD, MS, outlines treatment sequencing considerations for KRAS- and BRAF-targeted therapies in NSCLC.

Closing Perspectives: Unmet Needs, Emerging Advances, and the Future of Early-Stage NSCLC Treatment

August 12th 2025

Panelists discuss how future advances will focus on biomarker-driven personalized approaches, platform trials to increase pathologic complete response rates, circulating tumor DNA (ctDNA)-guided therapy escalation and de-escalation, and the critical importance of comprehensive molecular testing in the neoadjuvant setting.

FDA Approves Oncomine Dx Target Test as Zongertinib Companion Diagnostic in Nonsquamous NSCLC With HER2 TKD Mutations

August 11th 2025

The FDA has approved the Oncomine Dx Target Test as a companion diagnostic for zongertinib in NSCLC harboring HER2 TKD mutations.

The OncFive: Top Oncology Articles for the Week of 8/3

August 9th 2025

The FDA grants accelerated approval to zongertinib in lung cancer, clears dordaviprone in glioma, and awards priority review to liso-cel sBLA in MZL.

Dr Florez on Emerging Strategies to Address Checkpoint Inhibitor Resistance in NSCLC

August 8th 2025

Narjust Florez, MD, discusses emerging strategies to address immune checkpoint inhibitor resistance in non–small cell lung cancer.

Dr Dietrich on the FDA Approval of Zongertinib for HER2 TKD–Mutated Nonsquamous NSCLC

August 8th 2025

Martin Dietrich, MD, PhD, discusses the FDA accelerated approval of zongertinib for HER2-mutated or metastatic nonsquamous NSCLC.

FDA Grants Accelerated Approval to Zongertinib for Nonsquamous NSCLC With HER2 TKD Mutations

August 8th 2025

The FDA granted accelerated approval to zongertinib for pretreated, unresectable or metastatic non–small cell lung cancer harboring HER2 mutations.

NSCLC Experts Highlight Clinical Trials to Watch in 2025

August 8th 2025

Lung cancer experts share upcoming, potentially practice-informing clinical trials that are expected to read out in the second half of 2025.

ASCO Updates Living Guidelines to Include New Treatment Strategies for NSCLC With/Without Driver Alterations

August 7th 2025

ASCO updated their clinical practice guidelines for stage IV NSCLC with or without a driver alteration.

How Immunotherapy Could Continue to Affect Early-Stage NSCLC Management

August 7th 2025

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss how immunotherapy could continue to reshape early NSCLC management.

Factors Influencing Adjuvant Treatment Decisions in Early-Stage NSCLC

August 7th 2025

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss factors that affect adjuvant treatment decisions in early non–small cell lung cancer.

NCCN Adds LEMS Antibody Testing, Treatment Recommendations to Clinical Practice Guidelines in SCLC

August 7th 2025

The NCCN Clinical Practice Guidelines in Oncology for SCLC added new recommendations for LEMS, the use of amifampridine, and VGCC antibody testing.

Dr Cascone on Perioperative Nivolumab in Resectable NSCLC

August 5th 2025

Tina Cascone, MD, PhD, discusses of perioperative nivolumab vs placebo in patients with resectable non–small cell lung cancer.

PACIFIC-R 5-Year Follow-Up: Real-World Outcomes and Implications for Unresectable NSCLC Treatment

August 5th 2025

Panelists discuss how the PACIFIC-R real-world data demonstrates excellent long-term outcomes with a median survival of 60 months, validating the durvalumab consolidation approach while addressing management strategies for patients who progress on or after immunotherapy.